Evidence map›Paper›PMID 32271583›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2020

Surface Modification Using Ultraviolet-Ozone Treatment Enhances Acute Drug Transfer in Drug-Coated Balloon Therapy.

Dara Azar, Jared T Lott, Ehsan Jabbarzadeh, Tarek Shazly, Vijaya B Kolachalama

Open access · greenAbstract read
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jared T Lott
Ehsan Jabbarzadeh
Tarek Shazly
Vijaya B KolachalamaHariri Institute for Computing and Computational Science and Engineering, Boston University, Boston, Massachusetts 02215, United States.ORCID 0000-0002-5312-8644
University of South Carolina · USBoston University · US

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
Mechanisms of drug-coated balloon therapyR01HL159620 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOLACHALAMA, VIJAYA B. · 2021 to 2024
$2.1M
NHLBI NIH HHS R01 HL159620NIGMS NIH HHS P20 GM103499
6 · The paper itself

Abstract

Endovascular deployment of drug-coated balloons (DCB) is an emerging strategy for the revascularization of arterial disease. Randomized clinical trials have demonstrated DCB effectiveness, but a recent meta-analysis reported increased mortality risk in humans with use of DCBs containing the common antiproliferative drug paclitaxel. While many factors could have contributed to adverse outcomes, current DCB designs have poor drug delivery efficiency, risk of systemic toxicity, and limited potential to retain therapeutic drug concentrations within the arterial wall following the procedure. Our study focuses on developing a strategy to enhance acute drug transfer from the balloon to the arterial wall over the short procedural window (∼30-120 s). We employed ultraviolet-ozone plasma (UVO) treatment to increase the hydrophilicity of a prototypical balloon material (Nylon-12) and subsequently applied a urea-paclitaxel coating previously shown to undergo favorable adhesive interactions with the arterial wall under simulated ex-vivo deployment. A series of assays were performed to characterize our experimental DCBs in terms of UVO-induced alterations in balloon surface hydrophobicity, formed coating microstructure, coating stability, and acute drug transfer to the arterial wall. Obtained results suggest that the UVO-based surface modification of angioplasty balloons is a promising design strategy and highlights the critical role of coating microstructure in determining the drug transfer efficiency in DCB therapy.

Indexed as

Cardiovascular AgentsOzonePeripheral Arterial DiseasePharmaceutical PreparationsCoated Materials, BiocompatibleHumansPaclitaxelTime FactorsTreatment OutcomeCardiovascular AgentsCoated Materials, BiocompatibleOzonePaclitaxelPharmaceutical Preparations

Identifiers

PMID32271583
PMCPMC9337626
OpenAlexW3015715593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.